GoodRx (NASDAQ:GDRX) Issues Quarterly Earnings Results

GoodRx (NASDAQ:GDRX) announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09, FiscalAI reports. The firm had revenue of $194.79 million for the quarter, compared to analysts’ expectations of $193.27 million. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned $0.09 earnings per share.

GoodRx Stock Down 4.9%

NASDAQ:GDRX traded down $0.10 on Friday, reaching $1.94. 1,555,345 shares of the stock traded hands, compared to its average volume of 3,135,060. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $664.59 million, a price-to-earnings ratio of 21.56, a PEG ratio of 1.42 and a beta of 1.52. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81. The company’s fifty day simple moving average is $2.28 and its 200 day simple moving average is $2.99.

Wall Street Analysts Forecast Growth

GDRX has been the subject of several recent analyst reports. Citigroup reduced their price target on GoodRx from $4.50 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Wells Fargo & Company cut their price objective on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Morgan Stanley reduced their target price on GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Leerink Partners restated an “outperform” rating and set a $3.00 target price on shares of GoodRx in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $3.98.

Institutional Trading of GoodRx

Large investors have recently made changes to their positions in the stock. Quarry LP bought a new stake in GoodRx during the third quarter valued at about $33,000. MML Investors Services LLC bought a new position in shares of GoodRx in the fourth quarter worth about $36,000. DRW Securities LLC purchased a new position in shares of GoodRx during the 4th quarter valued at about $40,000. Boothbay Fund Management LLC purchased a new position in shares of GoodRx during the 3rd quarter valued at about $43,000. Finally, EP Wealth Advisors LLC bought a new position in shares of GoodRx during the 4th quarter valued at approximately $44,000. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.